Swedish biopharmaceutical company Mendus reported a second-quarter net loss of SEK 21.38 million, down from SEK 31.2 million in the same period last year, as its blood cancer therapy Vididencel progresses through clinical trials.
The company, which develops treatments for myeloid blood cancers including acute and chronic myeloid leukemia, posted an adjusted loss per share of SEK 0.34 for the three-month period. Revenue remained at zero during the quarter, reflecting the pre-commercial stage of its pipeline.
Mendus narrowed its operating loss to SEK 20.50 million from SEK 29.8 million in the prior-year quarter. The company attributed the improved financial performance to disciplined cost management amid advancing clinical programs.
Vididencel, Mendus’s lead asset targeting chronic and acute myeloid leukemia, remains the primary focus of its development strategy. The company has established a Clinical Advisory Board composed of international experts to guide its clinical development efforts.
In a strategic move to expand its research capabilities, Mendus entered a collaboration with the South Australian Health and Medical Research Institute to prepare for a new chronic myeloid leukemia trial. This partnership aims to accelerate the initiation of the VITAL-TFR2 trial, expected to commence in the second half of 2026.
Clinical catalysts for Vididencel are anticipated throughout 2026, including an initial readout from the VITAL-CML trial in chronic myeloid leukemia, scheduled for the second half of the year. Additional trial initiations and data updates are expected to provide further momentum to the program as Mendus advances its pipeline toward potential regulatory submissions.
